Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?

Hamdan Hamdan, Shahrukh K. Hashmi, Hillard Lazarus, Robert Peter Gale, Wenchun Qu, Riad El Fakih

Research output: Contribution to journalReview articlepeer-review

Abstract

Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative properties. MSCs are being studied as a therapy option for many inflammatory and immune disorders and are approved to treat acute graft-versus-host disease (GvHD). The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and associated coronavirus infectious disease-19 (COVID-19) has claimed many lives. Innovative therapies are needed. Preliminary data using MSCs in the setting of acute respiratory distress syndrome (ARDS) in COVID-19 are emerging. We review mechanisms of action of MSCs in inflammatory and immune conditions and discuss a potential role in persons with COVID-19.

Original languageEnglish (US)
Article number100742
JournalBlood Reviews
Volume46
DOIs
StatePublished - Mar 2021

Keywords

  • COVID-19
  • Mesenchymal stromal cell
  • SARS-CoV2

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?'. Together they form a unique fingerprint.

Cite this